CELECOXIB-D7

Celecoxib-d₇ is intended for use as an internal standard for the quantification of celecoxib by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC₅₀s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively). It displays chemopreventive activity in multiple tumor types via proapoptotic effects that are independent of COX-2 inhibition. Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events.

Celecoxib-d7 is the labeled analogue of Celecoxib (C251000), a selective cyclooxygenase-2 (COX-2) inhibitor. Anti-inflammatory. Used in treatment of familial adenomatous polyposis.

[1] MD.JASHIM UDDIN  Edward E K  P N Praveen Rao. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere[J]. Bioorganic & Medicinal Chemistry, 2003, 11 23: Pages 5273-5280. DOI: 10.1016/j.bmc.2003.07.005
[2] I A MARDINI  G A F. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.[J]. Molecular interventions, 2001, 1 1: 30-38.
[3] VERENA JENDROSSEK  Claus B  René Handrick. Celecoxib activates a novel mitochondrial apoptosis signaling pathway[J]. FASEB Journal, 2003, 17 11: 1-25. DOI: 10.1096/fj.02-0947fje
[4] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[5] JIUXIANG ZHU. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.[J]. Cancer research, 2004, 64 12: 4309-4318. DOI: 10.1158/0008-5472.can-03-4063